329 related articles for article (PubMed ID: 11460960)
21. Analysis of the cause of increased measles incidence in Xinjiang, China in 2004.
Yu X; Wang S; Guan J; Mahemuti ; Purhati ; Gou A; Liu Q; Jin X; Ghildyal R
Pediatr Infect Dis J; 2007 Jun; 26(6):513-8. PubMed ID: 17529869
[TBL] [Abstract][Full Text] [Related]
22. National serologic survey of measles immunity among persons 6 years of age or older, 1988-1994.
Hutchins SS; Redd SC; Schrag S; Kruszon-Moran D; Wooten K; McQuillan GM; Bellini W; Meyer PA; Hadler S
MedGenMed; 2001 Jan; ():E5. PubMed ID: 11320344
[TBL] [Abstract][Full Text] [Related]
23. Population immunity to measles in the United States, 1999.
Hutchins SS; Bellini WJ; Coronado V; Jiles R; Wooten K; Deladisma A
J Infect Dis; 2004 May; 189 Suppl 1():S91-7. PubMed ID: 15106096
[TBL] [Abstract][Full Text] [Related]
24. Two doses of measles vaccine: are some states in India ready for it?
John S; Sanghi S; Prasad S; Bose A; George K
J Trop Pediatr; 2009 Aug; 55(4):253-6. PubMed ID: 18799515
[TBL] [Abstract][Full Text] [Related]
25. The epidemiology of measles in England and Wales since the 1994 vaccination campaign.
Gay N; Ramsay M; Cohen B; Hesketh L; Morgan-Capner P; Brown D; Miller E
Commun Dis Rep CDR Rev; 1997 Feb; 7(2):R17-21. PubMed ID: 9046124
[TBL] [Abstract][Full Text] [Related]
26. Distinguishing between primary measles infection and vaccine failure reinfection by IgG avidity assay.
Hamkar R; Mahmoodi M; Nategh R; Jelyani KN; Eslami MB; Mohktari-Azad T
East Mediterr Health J; 2006 Nov; 12(6):775-82. PubMed ID: 17333822
[TBL] [Abstract][Full Text] [Related]
27. Trend of measles morbidity in Thailand.
Ariyasriwatana C
J Med Assoc Thai; 2003 Aug; 86 Suppl 3():S707-18. PubMed ID: 14700171
[TBL] [Abstract][Full Text] [Related]
28. Measles antibody prevalence after mass immunization in São Paulo, Brazil.
Pannuti CS; Moraes JC; Souza VA; Camargo MC; Hidalgo NT
Bull World Health Organ; 1991; 69(5):557-60. PubMed ID: 1959156
[TBL] [Abstract][Full Text] [Related]
29. Measles seroepidemiology among adolescents and young adults: response to revaccination.
Saffar MJ; Alraza-Amiri M; Ajami A; Baba-Mahmoodi F; Khalilian AR; Vahidshahi C; Shamsizadeh A
East Mediterr Health J; 2006 Sep; 12(5):573-81. PubMed ID: 17333796
[TBL] [Abstract][Full Text] [Related]
30. Impact of mass measles campaigns among children less than 5 years old in Uganda.
Nanyunja M; Lewis RF; Makumbi I; Seruyange R; Kabwongera E; Mugyenyi P; Talisuna A
J Infect Dis; 2003 May; 187 Suppl 1():S63-8. PubMed ID: 12721893
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of measles and rubella vaccines in Oman: a prospective clinical trial.
Kohler KA; Suleiman AJ; Robertson SE; Malankar P; Al-Khusaiby S; Helfand RF; Brown D; Bellini WJ; Sutter RW
J Infect Dis; 2003 May; 187 Suppl 1():S177-85. PubMed ID: 12721911
[TBL] [Abstract][Full Text] [Related]
32. A long-term follow-up study on the efficacy of further attenuated live measles vaccine, Biken CAM vaccine.
Isomura S; Morishima T; Nishikawa K; Hanada N; Rahman M; Terashima M; Kido S; Ueda S; Takahashi M
Biken J; 1986 Mar; 29(1):19-26. PubMed ID: 3778422
[TBL] [Abstract][Full Text] [Related]
33. [Measles: immunity and vaccination status in Greater Frankfurt on the Main].
Friedrichs I; Doerr HW; Allwinn R
Dtsch Med Wochenschr; 2012 Jan; 137(4):121-5. PubMed ID: 22259164
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the immunogenicity and safety of measles vaccine administered alone or with live, attenuated Japanese encephalitis SA 14-14-2 vaccine in Philippine infants.
Gatchalian S; Yao Y; Zhou B; Zhang L; Yoksan S; Kelly K; Neuzil KM; Yaïch M; Jacobson J
Vaccine; 2008 Apr; 26(18):2234-41. PubMed ID: 18394765
[TBL] [Abstract][Full Text] [Related]
35. EPI vaccines-induced antibody prevalence in 8-9 year-olds in The Gambia.
Viviani S; Mendy M; Jack AD; Hall AJ; Montesano R; Whittle HC
Trop Med Int Health; 2004 Oct; 9(10):1044-9. PubMed ID: 15482396
[TBL] [Abstract][Full Text] [Related]
36. [Measles and mumps antibody concentrations in newborns and their mothers--follow up first year of life].
Hohendahl J; Peters N; Hüttermann U; Rieger C
Klin Padiatr; 2006; 218(4):213-20. PubMed ID: 16819702
[TBL] [Abstract][Full Text] [Related]
37. Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: a serological study within a randomised trial of different measles vaccines.
Martins C; Garly ML; Bale C; Rodrigues A; Benn CS; Whittle H; Aaby P
Vaccine; 2013 Nov; 31(48):5766-71. PubMed ID: 23994379
[TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of standard-titer measles vaccine in HIV-1-infected and uninfected Zambian children: an observational study.
Moss WJ; Scott S; Mugala N; Ndhlovu Z; Beeler JA; Audet SA; Ngala M; Mwangala S; Nkonga-Mwangilwa C; Ryon JJ; Monze M; Kasolo F; Quinn TC; Cousens S; Griffin DE; Cutts FT
J Infect Dis; 2007 Aug; 196(3):347-55. PubMed ID: 17597448
[TBL] [Abstract][Full Text] [Related]
39. Waning antibodies in measles and rubella vaccinees--a longitudinal study.
Kremer JR; Schneider F; Muller CP
Vaccine; 2006 Mar; 24(14):2594-601. PubMed ID: 16427163
[TBL] [Abstract][Full Text] [Related]
40. [A study on the level of antibody against measles through maternal-fetal transfer and the immuno-response to measles vaccine among 4 to 7 month olds].
Liu BY; Feng ZX; Xu AQ
Zhonghua Liu Xing Bing Xue Za Zhi; 1995 Oct; 16(5):263-5. PubMed ID: 8706090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
